Patents by Inventor Shaomeng Wang

Shaomeng Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210309666
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1a, R1b, R2a, R2b, R3a, R3b, R4, A, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to degradation of MDM2 protein.
    Type: Application
    Filed: June 9, 2021
    Publication date: October 7, 2021
    Inventors: Shaomeng Wang, Angelo Aguilar, Yangbing Li, Jiuling Yang, Donna McEachern
  • Publication number: 20210284657
    Abstract: The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Application
    Filed: September 13, 2017
    Publication date: September 16, 2021
    Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Bing Zhou, Zhuo Chen, Ester Fernandez-Salas, Longchuan Bai, Donna McEachern
  • Patent number: 11110090
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: September 7, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Jianyong Chen
  • Publication number: 20210236474
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, and R4 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 5, 2021
    Inventors: Shaomeng Wang, Rohan Rej
  • Publication number: 20210198237
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Application
    Filed: November 23, 2020
    Publication date: July 1, 2021
    Inventors: Shaomeng Wang, Angelo Aguilar, Ke Zheng, Shilin Xu, Tianfeng Xu, Denzil Bernard, Liyue Huang
  • Patent number: 11046709
    Abstract: The present disclosure provides fused 1,4-diazepines represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, E, R1, R2, R3, R4, R5, and Ar are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds having Formula (I) to treat diseases, conditions, or disorders responsive to inhibition of BET bromodomain proteins such as cancer.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: June 29, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Jiantao Hu, Fuming Xu
  • Patent number: 11045448
    Abstract: The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 29, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Angelo Aguilar, Shilin Xu, Liyue Huang, Jeanne Stuckey, Tianfeng Xu
  • Patent number: 11046703
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1a, R1b, R2a, R2b, R3a, R3b, R4, A, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to degradation of MDM2 protein.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: June 29, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Angelo Aguilar, Yangbing Li, Jiuling Yang, Donna McEachern
  • Publication number: 20210188870
    Abstract: The present disclosure provides fused 1,4-oxazepines and related analogs represented by Formula (I) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, A, and Y are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a condition or disorder responsive to inhibition of BET bromodomains such as cancer.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 24, 2021
    Inventors: Shaomeng WANG, Bing ZHOU, Yang HU, Chao-Yie YANG, Chong QIN
  • Publication number: 20210130401
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3a, R3b, R4a, R4b, R5a and R5b are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition, disease, or disorder responsive to inhibition of the WDR5 interaction with its binding partners including, but not limited to, the WDR5-MLL protein-protein interaction.
    Type: Application
    Filed: May 15, 2018
    Publication date: May 6, 2021
    Inventors: Shaomeng Wang, Yangbing Li, Hacer Karatas, Liu Liu, Jeanne Stuckey, Yali Dou, Liyue Huang, Atsunori Kaneshige
  • Publication number: 20210115018
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R1c, R1d, R1e, R2, R3, R8a, R8b, L, X, Z1, and Z2 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Application
    Filed: March 29, 2019
    Publication date: April 22, 2021
    Applicant: The Regents of the University of Michigan
    Inventors: Shaomeng WANG, Shilin XU, Angelo AGUILAR, Liyue HUANG, Jeanne STUCKEY, Meng ZHANG
  • Patent number: 10975093
    Abstract: The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 13, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Weiguo Xiang, Bing Zhou
  • Publication number: 20210087188
    Abstract: The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, R8, E, Z, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Application
    Filed: March 21, 2019
    Publication date: March 25, 2021
    Applicant: The Regents oof the University of Michigan
    Inventors: Jianyong CHEN, Liu LIU, Xuyuan DONG, Chao-Yie YANG, Donna McEACHERN, Shaomeng WANG, Yunlong ZHOU, Yu JING
  • Patent number: 10956395
    Abstract: There is provided an association analysis method and apparatus. An original database is divided into projection databases, each not contributing to a support count of a frequent item set of another. The projection databases are used for sequential-pattern association analysis performed respectively by nodes corresponding to the projection databases. Local frequent item sets and corresponding support counts obtained by the nodes are combined. Since an established projection database does not contribute a support count of a frequent item set of another projection database, different nodes can perform association mining, including pruning, on different projection databases respectively.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 23, 2021
    Assignee: ALIBABA GROUP HOLDING LIMITED
    Inventors: Bin Dai, Xu Yang, Xiaoyan Jiang, Ning Cai, Shaomeng Wang
  • Patent number: 10899738
    Abstract: The present disclosure provides compounds by Formula (I): (Formula (I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 26, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Angelo Aguilar, Ke Zheng, Shilin Xu, Tianfeng Xu, Denzil Bernard, Liyue Huang
  • Publication number: 20210002277
    Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b, E, and are as defined as set forth in the specification.
    Type: Application
    Filed: September 17, 2020
    Publication date: January 7, 2021
    Inventors: Shaomeng Wang, Jianyong Chen
  • Patent number: 10829488
    Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b E, and = are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: November 10, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Jianyong Chen
  • Publication number: 20200330464
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Application
    Filed: June 29, 2020
    Publication date: October 22, 2020
    Inventors: Shaomeng Wang, Jianyong Chen
  • Patent number: 10781208
    Abstract: The present disclosure provides compounds represented by Formula (I), and the pharmaceutically acceptable salts and solvates thereof wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, E and (B) are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: September 22, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jianyong Chen, Liu Liu, Xuyuan Dong, Chao-Yie Yang, Donna McEachern, Shaomeng Wang
  • Publication number: 20200277305
    Abstract: The present disclosure provides compounds represented by Formula (I): Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Y, ?, Ar, W, L, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I)I for use to treat a condition or disorder responsive to inhibition and/or degradation of BET bromodomains such as cancer.
    Type: Application
    Filed: September 12, 2018
    Publication date: September 3, 2020
    Inventors: Shaomeng Wang, Weiguo Xiang, Fuming Xu, Longchuan Bai, Ester Fernandez-Salas, Donna McEachern